Simulations Plus

First quarter net revenues of $7.5 million reflecting 6.6% year over year growth. Board of Directors announces quarterly dividend of $0.06 per share

Substantial update of liver safety software includes new science and practical extensions

Conference Call to be on Wednesday, January 9, 2019, at 4:15 p.m. EST

Simulations Plus today reported results for the 4th quarter and fiscal year 2018. FY18 revenues increased 23%; earnings per share increased 51.4%.
Full Fiscal Year Pharmaceutical Software and Services Revenues Up 22.9%; Earnings per share of $0.50, up 51.4% over prior year

Conference Call to be on Wednesday, November 14, 2018, at 4:15 PM ET

RENAsym consortium will use QST to predict and investigate drug-induced kidney injury across various patient groups

Simulations Plus announced today that is board of directors has declared a cash dividend of $0.06 per share, to be distributed on Nov. 8, 2018.

Simulations Plus today announced today a new funded cooperative agreement with the FDA to work on the GastroPlus dermal absorption/PBPK (TCAT) model.

Simulations Plus announced today that it received an extension to its funded research collaboration with the FDA to develop the GastroPlus OCAT model.

Simulations Plus subsidiary DILIsym was awarded a Fast-Track SBIR grant to fund the development of software for predicting drug-induced kidney injury.

Enhancements to mechanistic dermal absorption model in GastroPlus™ will target non-pharmaceutical markets

Record quarter as revenues grow 26.7%, 9MoFY18 net income up 63.8%
Board of Directors Announces Quarterly Dividend of $0.06 Per Share

Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report its third quarter financial results for fiscal year 2018, the period ended May 31, 2018, after the close of the financial markets on Tuesday, July 10, 2018.

Improvements to AI technology and extensions to HTPK Simulation Module further support discovery research efforts

Executive with relevant expertise in multiple industries succeeds retiring CEO Walt Woltosz, who remains chairman of the board

Significant improvements support internal research activities through regulatory interactions